That's great you're tracking the latest research! Here's some of what's new with Rett and Dravet Syndromes:

**Dravet Syndrome* Gene therapies targeting the SCN1A gene mutation are showing promise. Zorevunersen has demonstrated long-term seizure reductions and improvements in EEG, behavior, and quality of life. A mouse study showed that AAV-mediated SCN1A gene replacement therapy alleviated Dravet symptoms without toxicity. Also, CHOP research links autism traits and cognitive issues in Dravet to VIP interneuron dysfunction, suggesting targets for therapies. You can find more info on enrolling in the Phase 3 trials at EmperorStudy.com.

**Rett Syndrome* Gene replacement therapy is considered optimal for curing Rett syndrome (RTT) by addressing MeCP2 mutations, with preclinical reversals of symptoms like autism, intellectual disability, and motor issues.